Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Purchases 455,753 Shares of Scholar Rock Holding Corporation $SRRK

Key Points

• Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. increased its stake in Scholar Rock Holding Corporation by 145.3%, acquiring an additional 455,753 shares during the second quarter, bringing its total holdings to 769,442 shares.
• Scholar Rock's stock price opened at $39.46 and the company's market cap is approximately $3.79 billion, with a P/E ratio of -13.56.
• Several analysts have rated Scholar Rock with an average rating of "Buy" and a consensus price target of $47.00, while the company recently reported an EPS of ($0.98), missing estimates.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. raised its position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 145.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 769,442 shares of the company's stock after purchasing an additional 455,753 shares during the period. Scholar Rock makes up approximately 3.2% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s holdings, making the stock its 17th largest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned approximately 0.81% of Scholar Rock worth $27,254,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SRRK. KLP Kapitalforvaltning AS increased its position in shares of Scholar Rock by 13.7% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 14,100 shares of the company's stock valued at $499,000 after purchasing an additional 1,700 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Scholar Rock by 15.8% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,668 shares of the company's stock valued at $130,000 after acquiring an additional 500 shares during the last quarter. AMI Asset Management Corp purchased a new position in shares of Scholar Rock during the second quarter worth approximately $1,048,000. E. Ohman J or Asset Management AB raised its stake in shares of Scholar Rock by 12.9% during the second quarter. E. Ohman J or Asset Management AB now owns 64,568 shares of the company's stock worth $2,287,000 after acquiring an additional 7,383 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Scholar Rock by 6.6% in the 1st quarter. Rhumbline Advisers now owns 120,752 shares of the company's stock worth $3,882,000 after acquiring an additional 7,491 shares during the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Scholar Rock Stock Performance

Scholar Rock stock opened at $39.46 on Friday. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 0.21. The firm has a market cap of $3.79 billion, a P/E ratio of -13.56 and a beta of 0.42. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $46.98. The firm has a 50-day moving average of $34.06 and a 200-day moving average of $33.37.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.32). During the same quarter last year, the company earned ($0.60) earnings per share. Sell-side analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wedbush reaffirmed an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a report on Wednesday, June 18th. Leerink Partners started coverage on Scholar Rock in a research note on Monday, September 15th. They set an "outperform" rating and a $51.00 price objective on the stock. Raymond James Financial set a $53.00 price objective on Scholar Rock and gave the stock a "strong-buy" rating in a report on Wednesday, July 30th. Leerink Partnrs raised Scholar Rock to a "strong-buy" rating in a research note on Monday, September 15th. Finally, Bank of America assumed coverage on Scholar Rock in a research report on Thursday. They set a "buy" rating and a $53.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Scholar Rock presently has an average rating of "Buy" and a consensus price target of $47.00.

Insiders Place Their Bets

In other news, Director Jeffrey S. Flier sold 11,136 shares of the firm's stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $40.02, for a total value of $445,662.72. Following the completion of the sale, the director directly owned 24,070 shares of the company's stock, valued at approximately $963,281.40. This trade represents a 31.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $32.53, for a total transaction of $32,725.18. Following the sale, the director directly owned 33,914 shares in the company, valued at $1,103,222.42. The trade was a 2.88% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,673 shares of company stock worth $687,751 in the last ninety days. Insiders own 13.30% of the company's stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.